Bone healing induced by local delivery of an engineered parathyroid hormone prodrug

被引:84
作者
Arrighi, Isabelle [1 ]
Mark, Silke [1 ]
Alvisi, Monica [1 ]
von Rechenberg, Brigitte [2 ]
Hubbell, Jeffrey A. [3 ]
Schense, Jason C. [1 ]
机构
[1] Kuros Biosurg AG, CH-8005 Zurich, Switzerland
[2] Univ Zurich, Vetsuisse Fac, Equine Hosp, Musculoskeletal Res Unit, CH-8057 Zurich, Switzerland
[3] Ecole Polytech Fed Lausanne, Swiss Fed Inst Technol, Inst Bioengn, Lab Regenerat Med & Pharmacobiol, CH-1015 Lausanne, Switzerland
关键词
Bone healing; Bone graft; Fibrin; Peptide; Osteoblast; PROTEIN-KINASE-A; IN-VIVO BEHAVIOR; GROWTH-FACTOR-I; CROSS-LINKING; FIBRIN MATRICES; PEPTIDES; RAT; TRANSGLUTAMINASE; BIOCOMPATIBILITY; OSTEOPOROSIS;
D O I
10.1016/j.biomaterials.2008.12.023
中图分类号
R318 [生物医学工程];
学科分类号
100103 [病原生物学];
摘要
Regenerative medicine requires innovative therapeutic designs to accommodate high morphogen concentrations in local depots, provide their sustained presence, and enhance cellular invasion and directed differentiation. Here we present an example for inducing local bone regeneration with a matrix-bound engineered active fragment of human parathyroid hormone (PTH1-34), linked to a transglutaminase substrate for binding to fibrin as a delivery and cell-invasion matrix with an intervening plasmin-sensitive link (TGpIPTH(1-34)). The precursor form displays very little activity and signaling to osteoblasts, whereas the plasmin cleavage product, as it would be induced under the enzymatic influence of cells remodeling the matrix, was highly active. In vivo animal bone-defect experiments showed dose-dependent bone formation using the PTH-fibrin matrix, with evidence of both osteoconductive and osteoinductive bone-healing mechanisms. Results showed that this PTH-derivatized matrix may have potential utility in humans as a replacement for bone grafts or to repair bone defects. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1763 / 1771
页数:9
相关论文
共 50 条
[1]
In vivo behavior of three different injectable hydraulic calcium phosphate cements [J].
Apelt, D ;
Theiss, F ;
El-Warrak, AO ;
Zlinszky, K ;
Bettschart-Wolfisberger, R ;
Bohner, M ;
Matter, S ;
Auer, JA ;
von Rechenberg, B .
BIOMATERIALS, 2004, 25 (7-8) :1439-1451
[2]
Complications of iliac crest bone graft harvesting [J].
Arrington, ED ;
Smith, WJ ;
Chambers, HG ;
Bucknell, AL ;
Davino, NA .
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 1996, (329) :300-309
[3]
Core histones are glutaminyl substrates for tissue transglutaminase [J].
Ballestar, E ;
Abad, C ;
Franco, L .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (31) :18817-18824
[4]
Use of the transglutaminase reaction to study the dissociation of histone N-terminal tails from DNA in nucleosome core particles [J].
Ballestar, E ;
Franco, L .
BIOCHEMISTRY, 1997, 36 (20) :5963-5969
[5]
Mechanisms balancing skeletal matrix synthesis and degradation [J].
Blair, HC ;
Zaidi, M ;
Schlesinger, PH .
BIOCHEMICAL JOURNAL, 2002, 364 (02) :329-341
[6]
Localized, direct plasmid gene delivery in vivo:: prolonged therapy results in reproducible tissue regeneration [J].
Bonadio, J ;
Smiley, E ;
Patil, P ;
Goldstein, S .
NATURE MEDICINE, 1999, 5 (07) :753-759
[7]
Research directions for bone healing [J].
Branfoot, T .
INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED, 2005, 36 :51-54
[8]
Carter Percy H., 2006, Endocrine Metabolic & Immune Disorders-Drug Targets, V6, P59
[9]
Enhancement of fracture healing with parathyroid hormone: preclinical studies and potential clinical applications [J].
Chalidis, Byron ;
Tzioupis, Christopher ;
Tsiridis, Eleftherios ;
Giannoudis, Peter V. .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (04) :441-449
[10]
Cheung Catherine, 2005, Clin Podiatr Med Surg, V22, P631, DOI 10.1016/j.cpm.2005.07.002